ca-170

CA-170 is an orally bioavailable dual inhibitor of VISTA and PD-L1 that selectively restores T-cell proliferation and effector function suppressed by immune checkpoint signaling, while demonstrating minimal off-target activity across a broad receptor and enzyme panel, making CA-170 a valuable compound for immuno-oncology research and immune checkpoint modulation studies.

Senicapoc (ICA-17043) is a potent inhibitor of the Gardos channel that ameliorates RBC dehydration in the SAD mouse. It blocks Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 ± 2 nM (CLT IC50 = 100 ± 12 nM) and inhibits RBC dehydration with an IC50 of 30 ± 20 nM. Senicapoc is used in the treatment of Sickle Cell Disease and Sickle Cell Anemia.